Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients

Carr, 1998, Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance, Lancet, 351, 1881, 10.1016/S0140-6736(98)03391-1 Flexner, 1998, HIV-protease inhibitors, N Engl J Med, 338, 1281, 10.1056/NEJM199804303381808 Riddle, 2001, HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus, J Biol Chem, 276, 37514, 10.1074/jbc.M104557200 Salmon-Ceron, 2001, Mitochondrial toxic effects and ribavirin, Lancet, 357, 1803, 10.1016/S0140-6736(00)04921-7 Brinkman, 1999, Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy, Lancet, 354, 1112, 10.1016/S0140-6736(99)06102-4 Carr, 2000, A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome, AIDS, 14, F25, 10.1097/00002030-200002180-00001 Masini, 1999, Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage, J Neurol Sci, 166, 131, 10.1016/S0022-510X(99)00126-4 Morris, 1999, HIV nucleoside analogues: new adverse effects on mitochondria?, Lancet, 354, 1046, 10.1016/S0140-6736(99)00301-3 Olano, 1995, Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine, Clin Infect Dis, 4, 973, 10.1093/clinids/21.4.973 Brivet, 2000, Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction?, J Hepatol, 32, 364, 10.1016/S0168-8278(00)80088-4 ter Hofstede, 2000, Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases, Int J STD AIDS, 11, 611, 10.1258/0956462001916498 Chariot, 1999, Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion, J Hepatol, 30, 156, 10.1016/S0168-8278(99)80020-8 Lonergan, 2000, Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens, Clin Infect Dis, 31, 162, 10.1086/313912 Boubaker, 2001, Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study, Clin Infect Dis, 33, 1931, 10.1086/324353 Brinkman, 2001, Management of hyperlactatemia: no need for routine lactate measurements, AIDS, 15, 795, 10.1097/00002030-200104130-00016 Simon, 1999, Mitochondrial disorders: clinical and genetic features, Annu Rev Med, 50, 111, 10.1146/annurev.med.50.1.111 Brinkman, 2000, Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors, Clin Infect Dis, 31, 167, 10.1086/313921 Cote, 2002, Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients, N Engl J Med, 346, 811, 10.1056/NEJMoa012035 Montaner, 2003, Mitochondrial toxicity in the era of HAART: evaluating venous lactae and peripheral blood mitochondrial DNA in HIV-infecting patients taking antiretroviral therapy, J Acquir Immune Defic Syndr, 34, S85, 10.1097/00126334-200309011-00013 Walker, 2002, Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors, AIDS, 16, 2165, 10.1097/00002030-200211080-00009 Henry, 2002, Lymphocyte mitochondrial biomarkers in asymptomatic HIV-1-infected individuals treated with nucleoside reverse transcriptase inhibitors, AIDS, 16, 2485, 10.1097/00002030-200212060-00018 McComsey, 2002, Analysis of mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy, AIDS, 16, 513, 10.1097/00002030-200203080-00001 Gahan, 2001, Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction, J Clin Virol, 22, 241, 10.1016/S1386-6532(01)00195-0 Ihaka, 1996, R: a language of data analysis and graphics, J Comput Graph Stat, 5, 299 Petit, 2003, Quantitation of blood lymphocyte mitochondrial dna for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion, J Acquir Immune Deficiency Syndrome, 33, 461, 10.1097/00126334-200308010-00006 Plymale, 1999, Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells, AIDS, 13, 1827, 10.1097/00002030-199910010-00004 Ferri, 2000, Mitochondrial control of cell death induced by HIV-1-encoded proteins, Ann NY Acad Sci, 926, 149, 10.1111/j.1749-6632.2000.tb05609.x Moretti, 2000, Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection:comparison between AIDS patients and asymptomatic long-term non-progressors, Clin Exp Immunol, 122, 364, 10.1046/j.1365-2249.2000.01375.x Roggero, 2001, Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling, J Virol, 7, 7637, 10.1128/JVI.75.16.7637-7650.2001 Mauss, 2000, HIV-associated lipodystrophy syndrome, AIDS, 14, S197 Carr, 1999, Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study, Lancet, 353, 2093, 10.1016/S0140-6736(98)08468-2 Mallal, 1999, Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy, San Diego [abstract 026], Antiviral Ther, 4, 42 Mallal, 2000, Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection, AIDS, 14, 1309, 10.1097/00002030-200007070-00002 Viard, 1999, Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a proteas inhibitor. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy, San Diego, 1999 [abstract 026], Antiviral Ther, 4, 47 Belloso, 2003, Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients, J Acquir Immune Deficiency Syndrome, 32, 104, 10.1097/00126334-200301010-00015 Bonnet, 2002, Metabolic acidosis in HIV-infected patients, Clin Infect Dis, 34, 1289, 10.1086/339954 Delgado, 2001, Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series, Clin Infect Dis, 33, 2072, 10.1086/323980 Gerard, 2000, Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy, AIDS, 14, 2723, 10.1097/00002030-200012010-00012 John, 2001, Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy, AIDS, 15, 717, 10.1097/00002030-200104130-00007 Birkus, 2002, Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon, Antimicrob Agents Chemother, 46, 1610, 10.1128/AAC.46.5.1610-1613.2002 Kakuda, 2000, Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity, Clin Ther, 22, 685, 10.1016/S0149-2918(00)90004-3 Lim, 2001, Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma, J Biol Chem, 276, 23616, 10.1074/jbc.M101114200